Broadcast series

Bridging Distances in PAH:
Bringing Best Practices to the People Through Telementoring

Overview
Learning Objectives
Faculty and Disclosures

Program Overview

Pulmonary Arterial Hypertension (PAH) demands a personalized, multidisciplinary approach, encompassing specialized knowledge and novel treatments, a requisite often unfulfilled in remote regions due to significant gaps in access, expertise, and resources. The dearth of specialized PH centers and the ensuing reliance on general practitioners, compounded by geographical isolation from expansive medical communities, accentuates the urgency of integrating innovative treatments and the latest clinical trial data to enhance patient outcomes and refine risk management strategies. Constrained resources in these areas further impede healthcare professionals' capacity to stay updated on groundbreaking guidelines, emergent therapies, and advancements in personalized, multidisciplinary care essential for managing PAH effectively. Complicating this scenario are prevailing technology and connectivity challenges, which curtail the adoption of telehealth initiatives and inhibit participation in telementoring programs — key conduits for disseminating knowledge on avant-garde therapies and clinical developments.  Consequently, a compelling need emerges for a strategic initiative, meticulously designed enable early detection, convey insights on current and novel treatments, disseminate pivotal clinical trial data, and elucidate strategies for individualized, multidisciplinary care to healthcare providers via telementoring. This initiative aspires to bridge the identified gaps, cultivate collaboration, and significantly elevate the standard of PAH management in underserved, resource-limited rural environments.   

Target Audience

This educational initiative is designed for pulmonologists, critical care, primary care physicians, nurse practitioners, physician assistants, surgeons, pharmacists, and nurses.

Learning Objectives

Upon completion of this activity, the participant should be able to:
  • SUMMARIZE best practices for decreasing the diagnostic interval in PAH.
  • EVALUATE the scientific evidence supporting the use of current and emerging therapeutics for PAH, discerning their current and potential roles in the treatment and management of this disease.
  • EXPLAIN how to implement newly refined risk assessment tools into practice even in remote settings.
  • INTEGRATE telehealth and telementoring practices, ensuring consistent remote access to specialized multidisciplinary teams for optimal care of PAH patients.

Disclosures of Relevant Financial Relationship(s)

​Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:
Nicholas Kolaitis, MD MAS
Assistant Professor, Medicine
University of California San Francisco
San Rafael, CA 
Disclosures:
Consulting Fee (e.g., Advisory Board):
Bayer, Janssen, United Therapeutics, Liquidia, Merck
Contracted Research (Principal Investigators must provide information, even if received by the institution): Site PI for clinical Trial: Merck, Liquidia
KATHARINE CLAPHAM, MD
Assistant Professor in Cardiology, Associate Director Pulmonary Hypertension and Dyspnea Program, Director of Pulmonary Vascular Research, University of Utah
Salt Lake City, UT
Disclosures:
Consulting Fee (e.g., Advisory Board): Amgen, Tectonic Therapeutics, United Therapeutics
Jean Marie Elwing, MD, FCCP
Professor of Medicine, Director of Pulmonary Hypertension Program
University of Cincinnati Pulmonary
Madeira, OH
Disclosures:
Consulting Fee (e.g., Advisory Board): United Therapeutics, Aerovate, Bayer, Gossamer Bio, Liquida, Acceleron/Merck, Janssen/Actelion/Johnson&Johnson, Roivant
Contracted Research (Principal Investigators must provide information, even if received by the institution): United Therapeutics, Gossamer Bio, Bayer, Acceleron/Merck, Altavant, Aerovate, Pharmosa/Liquidia, Actelion/Janssen/Johnson&Johnson, Lung LLC, Riovant
Honoraria: United Therapeutics
This educational activity was supported by independent educational grants from Merck Sharp & Dohme LLC and Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of
Johnson & Johnson.

Learning program contents